Navigation Links
PROLOR Biotech's Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
Date:9/27/2010

that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.PROLOR CONTACT:

MEDIA CONTACT:Shai Novik, President

Barbara LindheimPROLOR Biotech, Inc.

GendeLLindheim BioCom PartnersTel: +1 866 644-7811

+1 212 918-4650Email: shai@prolor-biotech.com
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
2. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
3. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
4. PROLOR Biotech to Present at the UBS 2009 Global Life Sciences Conference
5. PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone
6. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
7. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
8. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
9. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
10. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
11. UC Riverside researcher develops novel method to grow human embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Burlington, MA (PRWEB) October 31, 2014 ... is hosting a free learning webinar to introduce its ... managers, standards directors and biostatisticians. , Launched in September, ... the company's suite of clinical trial automation tools. For ... in a web browser. And by introducing Formations – ...
(Date:10/31/2014)... Brady (NYSE:BRC), a global leader in product ... video testimonial on the effectiveness of its FreezerBondz™ ... at the BloodCenter of Wisconsin discusses the challenges she ... of thousands of samples, and how the durability of ... we design our label materials with the harsh conditions ...
(Date:10/31/2014)... , Oct. 31, 2014  Tavistock Development ... by Tavistock Group, celebrated the groundbreaking of the ... City. The 92,000-square-foot, three-story facility ... Central Florida designed specifically for life ... the heart of the 650-acre Lake Nona Medical ...
(Date:10/30/2014)... 2014 Investor-Edge has initiated coverage ... ONVO), Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics ... (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). ... at: http://investor-edge.com/register . On Wednesday, October ... 0.33%, the Dow Jones Industrial Average declined 0.18%, to ...
Breaking Biology Technology:Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Brady Debuts New Lab Label Testimonial Video 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... Inc.,(Nasdaq: VSCP ), a leading provider of ... 25, 2009 it will release its 2008,fourth quarter and ... 2008. The company will host a conference call ... 11:00 a.m. EST. , VirtualScopics, ...
... Include: - Initiation of development activities to ... Receipt of GRAS (Generally Recognized As Safe) ... commercialization in the U.S. and elsewhere- New ... Continued activities to support regulatory filings for ...
... LAIYANG, China, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... pharmaceutical company with its principal operations,in the People,s Republic ... conference call at 9:00 a.m. Eastern on Tuesday, February ... ended December 31, 2008 of,its fiscal year 2009. , ...
Cached Biology Technology:VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement 2VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 14Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 2Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 3
(Date:10/30/2014)... DALLAS , Oct. 29, 2014 /PRNewswire/ ... and criminal justice technology solutions for public ... that it has deployed exciting enhancements to ... data analytics to provide actionable intelligence and ... Technologies continues to drive technological innovation through ...
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... City on September 19, 2014, leading geneticist and humanitarian ... Genome Sciences and Medicine at the University of Washington ... Tel Aviv University, was awarded the 2014 Lasker-Koshland Special ... her honorary degree from TAU, Prof. King was the ... and for the past 18 years she has been ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2
... in Biomed Central,s open access journal Journal of ... brain to develop Alzheimer,s disease. To date ... of inflammation in Alzheimer,s disease (AD), especially because trials ... ADAPT (The Alzheimer`s Disease Anti-inflammatory Prevention Trial) trial was ...
... Physics World, Steve Haake, director of the Centre for Sports ... the men,s 100 m sprint will be one event not ... the "performance-improvement index", which uses very simple physics to compare ... the last 100 years. The model shows that the ...
... next "next-gen" technology in genome sequencing has gotten a major ... Spring Harbor Laboratory (CSHL) and collaborators today published results of ... was recently introduced but whose use has so far been ... CSHL Assistant Professor Michael Schatz and Adam Phillippy and Sergey ...
Cached Biology News:Physics confirms sprinters are performing better than ever before 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 3
... The new D-LUX Detection Platform ... to provide the most sensitive, specific, ... qPCR. Invitrogens D-LUX Detection Platform offers ... equal to TaqMan probes, high signal/background ...
Provides continuous mixing action. For use with tubes, vials, and other containers...
... is aseptically collected via cardiac puncture from 3 ... mixed sex). It is then centrifuged and frozen ... filtered and bottled at 4C then stored at ... HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU CAN NOW ...
Modified and insect cell culture tested....
Biology Products: